David M. Jablons

20.5k citations

273 papers · 14.2k indexed · 1 hit paper · h-index 61

Impact in

Oncology top 0.2%
- Lung Cancer Research Studies
Pulmonary and Respiratory Medicine top 0.2%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Occupational and environmental lung diseases
- Pleural and Pulmonary Diseases

Papers in

Pulmonary and Respiratory Medicine 128
- Lung Cancer Treatments and Mutations 56
- Lung Cancer Diagnosis and Treatment 42
- Occupational and environmental lung diseases 34
Oncology 97
- Lung Cancer Research Studies 28

Co-authors: Liang You Zhidong Xu Biao He Frank McCormick Kazutsugu Uematsu Julien Mazières Amie Y. Lee Iwao Mikami
Journals: Journal of Thoracic Oncology (16 papers)Clinical Lung Cancer (13 papers)Oncotarget (12 papers)Oncogene (9 papers)Lung Cancer (9 papers)
Partner nations: United States China Taiwan

In The Last Decade

David M. Jablons

269 papers receiving 13.9k citations

Hit Papers

align trajectories log scale

Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer 2004 · 1.5k citations

Peers

Countries citing papers authored by David M. Jablons

Since Specialization

Citations

This map shows the geographic impact of David M. Jablons's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David M. Jablons with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David M. Jablons more than expected).

Fields of papers citing papers by David M. Jablons

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David M. Jablons. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David M. Jablons. The network helps show where David M. Jablons may publish in the future.

Co-authorship network

The 25 scholars most cited alongside David M. Jablons, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David M. Jablons Line = papers co-authored together David M. Jablons links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	The crystal structure of the protein kinase HIPK2 reveals a unique architecture of its CMGC-insert region Journal of Biological Chemistry ·Christopher Agnew, Lijun Liu, Dr.K Thippeswamy, Wei Xü, Liang You, Wayland Yeung, Natarajan Kannan, David M. Jablons, Natalia Jura	2019	24
2	Cul4A Modulates Invasion and Metastasis of Lung Cancer through Regulation of ANXA10 Cancers ·Ming‐Szu Hung, Yi-Chuan Chen, Paul-Yann Lin, M. Laptev, Chia‐Chen Hsu, Jrhau Lung, Liang You, Zhidong Xu, Jian‐Hua Mao, David M. Jablons, Cheng‐Ta Yang	2019	21
3	Inhibition of cyclin‐dependent kinase 7 down‐regulates yes‐associated protein expression in mesothelioma cells Journal of Cellular and Molecular Medicine ·Emilio Filieri, Arantza Guerra, Luwei Liu, Leda Gobbo Bueno de Freitas, Yucheng Wang, Anatoly Urisman, Yi‐Lin Yang, Shu Liu, Zhidong Xu, Bin Hu, Hui Li, David M. Jablons, Liang You	2019	7
4	<p>Differential gene expression identifies KRT7 and MUC1 as potential metastasis-specific targets in sarcoma</p> Cancer Management and Research ·Long Jiang, Bhairavi Tolani, Che‐Chung Yeh, Angelita Cattani Pereira, N.V. Shtabel, Andrew Horvai, F. Casanellas, Johannes R. Kratz, David M. Jablons, Michael J. Mann	2019	6
5	Applications of Next-Generation Sequencing in Neoantigen Prediction and Cancer Vaccine Development Genetic Testing and Molecular Biomarkers ·Elizabeth Lancaster, David M. Jablons, Johannes R. Kratz	2019	29
6	Inhibition of yes‐associated protein suppresses brain metastasis of human lung adenocarcinoma in a murine model Journal of Cellular and Molecular Medicine ·Ping‐Chih Hsu, Emilio Filieri, Zhen Huang, Yi‐Lin Yang, Zhidong Xu, Т. В. Нуркевич, Yuyuan Dai, Che‐Chung Yeh, Leda Gobbo Bueno de Freitas, Shu Liu, Anatoly Urisman, Cheng‐Ta Yang, David M. Jablons, Liang You	2018	26
7	Scientific Advances and New Frontiers in Mesothelioma Therapeutics Journal of Thoracic Oncology ·Luciano Mutti, Tobias Peikert, B. W. Robinson, Arnaud Scherpereel, Anne S. Tsao, Marc de Perrot, Gavitt A. Woodard, David M. Jablons, Jacinta Wiens, Fred R. Hirsch, Haining Yang, Michele Carbone, Anish Thomas, Raffit Hassan	2018	69
8	Targeting YAP in malignant pleural mesothelioma Journal of Cellular and Molecular Medicine ·Wenqian Zhang, Yuyuan Dai, Ping‐Chih Hsu, Hui Wang, Li Cheng, Yi‐Lin Yang, Yucheng Wang, Zhidong Xu, Shu Liu, Leda Gobbo Bueno de Freitas, Bin Hu, Hui Li, David M. Jablons, Liang You	2017	50
9	Identification of Recurrent FGFR3–TACC3 Fusion Oncogenes from Lung Adenocarcinoma Clinical Cancer Research ·Marzia Capelletti, Michael Dodge, Dalia Ercan, Peter S. Hammerman, Seung-Il Park, Young Tae Kim, Hidefumi Sasaki, David M. Jablons, Doron Lipson, Lauren Young, Phil Stephens, Vincent A. Miller, Neal I. Lindeman, Kiara J. Munir, William G. Richards, Pasi A. Jänne	2014	79
10	SULF2 expression by immunohistochemistry and overall survival in oesophageal cancer: a cohort study BMJ Open ·Natalie S. Lui, Annemieke van Zante, Steven D. Rosen, David M. Jablons, Hassan Lemjabbar‐Alaoui	2012	14
11	Organic Cation Transporters Modulate the Uptake and Cytotoxicity of Picoplatin, a Third-Generation Platinum Analogue Molecular Cancer Therapeutics ·Swati S. More, Shuanglian Li, Sook Wah Yee, Ligong Chen, Zhidong Xu, David M. Jablons, Kathleen M. Giacomini	2010	61
12	A multi-marker assay to distinguish malignant melanomas from benign nevi Proceedings of the National Academy of Sciences ·Mohammed Kashani–Sabet, Javier Rangel, Sima Torabian, Mehdi Nosrati, Jeff Simko, David M. Jablons, Dan H. Moore, Chris Haqq, James R. Miller, Richard W. Sagebiel	2009	76
13	Genomic Prognostic Models in Early-Stage Lung Cancer Clinical Lung Cancer ·Johannes R. Kratz, David M. Jablons	2009	32
14	A Multigene Assay Is Prognostic of Survival in Patients with Early-Stage Lung Adenocarcinoma Clinical Cancer Research ·Dan J. Raz, M. Ray, Alessandro Cazonatto Galvão, Biao He, Miquel Tarón, Marcin Skrzypski, Mark R. Segal, David R. Gandara, Rafael Rosell, David M. Jablons	2008	60
15	Three-Gene Expression Signature Predicts Survival in Early-Stage Squamous Cell Carcinoma of the Lung Clinical Cancer Research ·Marcin Skrzypski, Ewa Jassem, Miquel Tarón, José Javier Sánchez, Pedro Méndez, Witold Rzyman, Graff F Kischihoeffer R, Dan J. Raz, David M. Jablons, Mariano Provencio, Bartomeu Massutí, Imane Chaib, Laia Perez‐Roca, Jacek Jassem, Rafael Rosell	2008	84
16	Evaluation of a chemical library of small-molecule Dishevelled antagonists that suppress tumor growth by down-regulating T-cell factor–mediated transcription Molecular Cancer Therapeutics ·Liang You, Zhidong Xu, Chandanamali Punchihewa, David M. Jablons, Naoaki Fujii	2008	20
17	An Antagonist of Dishevelled Protein-Protein Interaction Suppresses β-Catenin–Dependent Tumor Cell Growth Cancer Research ·Naoaki Fujii, Liang You, Zhidong Xu, Kazutsugu Uematsu, Jufang Shan, Biao He, Iwao Mikami, Sarah N. Parry, Geoffrey Neale, Jie Zheng, R. Kiplin Guy, David M. Jablons	2007	187
18	SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer Proceedings of the National Academy of Sciences ·Biao He, Liang You, Kazutsugu Uematsu, Keling Zang, Zhidong Xu, Amie Y. Lee, J Costello, Frank McCormick, David M. Jablons	2003	312
19	Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma Journal of Thoracic and Cardiovascular Surgery ·N Baduge, Yi-Yu Kao, Hui‐Kuo G. Shu, Thierry Jahan, Mack Roach, Joycelyn L. Speight, Robert B. Cameron, Theodore L. Phillips, Albert Chan, David M. Jablons	2002	74
20	Aberrations in the fragile histidine triad (FHIT) gene in idiopathic pulmonary fibrosis. PubMed ·Kazutsugu Uematsu, Atsunori Yoshimura, Akihiko Gemma, Hiroshi Mochimaru, Yoko Hosoya, Shinobu Kunugi, Kuniko Matsuda, Masahiro Seike, Nadine Salwa, K. Takenaka, K Koizumi, Y Fukuda, Shigeo Tanaka, Kazuo Chin, David M. Jablons, S Kudoh	2001	49

About David M. Jablons

David M. Jablons is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Biotechnology, Cancer Research and Molecular Biology, having authored 273 papers that have together received 14.2k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (56 papers), Lung Cancer Diagnosis and Treatment (42 papers), Wnt/β-catenin signaling in development and cancer (41 papers), Cancer-related gene regulation (40 papers), Occupational and environmental lung diseases (34 papers), Epigenetics and DNA Methylation (30 papers), Lung Cancer Research Studies (28 papers) and Cancer Research and Treatments (21 papers). The work is most often cited by research in Oncology (4.8k citations), Pulmonary and Respiratory Medicine (5.2k citations), Cancer Research (2.0k citations), Molecular Biology (6.9k citations) and Immunology (1.5k citations). David M. Jablons has collaborated with scholars based in United States, China and Taiwan. Frequent co-authors include Liang You, Zhidong Xu, Biao He, Frank McCormick, Kazutsugu Uematsu, Julien Mazières, Amie Y. Lee, Iwao Mikami, John Nemunaitis and Cheng‐Ta Yang. Their work appears in journals such as Journal of Thoracic Oncology, Clinical Lung Cancer, Oncotarget, Oncogene and Lung Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact